Synthesis, aggregation, and neurotoxicity of the Alzheimer's Aβ1-42 amyloid peptide and its isoaspartyl isomers

被引:77
|
作者
Fukuda, H
Shimizu, T
Nakajima, M
Mori, H
Shirasawa, T
机构
[1] PE Biosyst Japan Ltd, Minato Ku, Tokyo 1060032, Japan
[2] Tokyo Metropolitan Inst Gerontol, Dept Mol Genet, Itabashi Ku, Tokyo 1730015, Japan
[3] Osaka City Univ, Sch Med, Dept Neurosci, Abeno Ku, Osaka 5458585, Japan
关键词
aggregation; Alzheimer's disease; beta-amyloid peptide; solid phase synthesis;
D O I
10.1016/S0960-894X(99)00121-3
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Amyloid A beta 1-42 peptide (A beta 1-42) and its isomers with an isoaspartyl residue at position 7 or 23 [A beta 1-42(isoAsp7) and A beta 1-42(isoAsp23)] were synthesized in high purity by the Fmoc-solid phase technique, followed by HPLC on a silica-based reversed-phase column under the basic conditions. Importantly, A beta 1-42(isoAsp23) aggregated more strongly than native A beta 1-42 and showed significant neurotoxicity, while the aggregation ability and neurotoxicity of A beta 1-42(isoAsp7) was weak. This suggests that the isomerization of the aspartyl residues plays an important role in fibril formation in Alzheimer's disease. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:953 / 956
页数:4
相关论文
共 50 条
  • [41] Methionine 35 oxidation reduces fibril assembly of the amyloid Aβ-(1-42) peptide of Alzheimer's disease
    Hou, LM
    Kang, I
    Marchant, RE
    Zagorski, MG
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (43) : 40173 - 40176
  • [42] A new evidence for DNA nicking property of amyloid β-peptide (1-42):: Relevance to Alzheimer's disease
    Suram, A.
    Hegde, M. L.
    Rao, K. S. J.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2007, 463 (02) : 245 - 252
  • [43] Decreased serum amyloid β1-42 autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid β1-42 peptide
    Brettschneider, S
    Morgenthaler, NG
    Teipel, SJ
    Fischer-Schulz, C
    Bürger, K
    Dodel, R
    Du, YS
    Möller, HJ
    Bergmann, A
    Hampel, H
    BIOLOGICAL PSYCHIATRY, 2005, 57 (07) : 813 - 816
  • [44] Resveratrol-mediated cleavage of amyloid β1-42 peptide: potential relevance to Alzheimer's disease
    Al-Edresi, Sarmad
    Alsalahat, Izzeddin
    Freeman, Sally
    Aojula, Harmesh
    Penny, Jeffrey
    NEUROBIOLOGY OF AGING, 2020, 94 : 24 - 33
  • [45] Nontoxic amyloid beta peptide (1-42) suppresses acetylcholine synthesis - Possible role in cholinergic dysfunction in Alzheimer's disease
    Hoshi, M
    Takashima, A
    Murayama, M
    Yasutake, K
    Yoshida, N
    Ishiguro, K
    Hoshino, T
    Imahori, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (04) : 2038 - 2041
  • [46] Role of amyloid β1-42 and neuroimaging biomarkers in Alzheimer's disease
    Lista, Simone
    Emanuele, Enzo
    BIOMARKERS IN MEDICINE, 2011, 5 (04) : 411 - 413
  • [47] Microchip Circulation Drastically Accelerates Amyloid Aggregation of 1-42 β-amyloid Peptide from Felis catus
    Gospodarczyk, Witold
    Kozak, Maciej
    ACS CHEMICAL NEUROSCIENCE, 2017, 8 (11): : 2558 - 2567
  • [48] Aβ1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible Aβ1-42 aggregation?
    Sancesario, Giulia M.
    Esposito, Zaira
    Nuccetelli, Marzia
    Bernardini, Sergio
    Sorge, Roberto
    Martorana, Alessandro
    Federici, Giorgio
    Bernardi, Giorgio
    Sancesario, Giuseppe
    EXPERIMENTAL NEUROLOGY, 2010, 223 (02) : 371 - 376
  • [49] Inhibition of amyloid β1-42 peptide aggregation by newly designed cyclometallated palladium complexes
    Saini, Rahul
    Navale, Govinda R.
    Singh, Sain
    Singh, Haobam Kisan
    Chauhan, Rahul
    Agrawal, Sonia
    Sarkar, Dhiman
    Sarma, Manabendra
    Ghosh, Kaushik
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2023, 248
  • [50] Exploring the Early Stages of the Amyloid Aβ(1-42) Peptide Aggregation Process: An NMR Study
    Santoro, Angelo
    Grimaldi, Manuela
    Buonocore, Michela
    Stillitano, Ilaria
    D'Ursi, Anna Maria
    PHARMACEUTICALS, 2021, 14 (08)